Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
---|---|
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00713947 |
Low dose of aspirin is the main cause of gastro-duodenal ulcer. The best prevention is not definite particularly in patients without history of ulcer and infected by H. pylori.The aim of the study is to evaluate the gastric damage induced by aspirin in patients with H. pylori infection but who have any history of ulcer.
Condition | Intervention | Phase |
---|---|---|
Positive Helicobacter Pylori Serology Coronary Thrombosis Supra-Aortic Artery Thrombosis |
Drug: during one week for the active treatments Drug: Pantoprazole Drug: Placebo Formula 515 |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Subject), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course |
Estimated Enrollment: | 549 |
Study Start Date: | July 2008 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Active Comparator
Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
|
Drug: during one week for the active treatments
during one week for the active treatments placebo during 25 weeks
|
B: Experimental
Pantoprazole
|
Drug: Pantoprazole
6 months at 20 mg
|
C: Placebo Comparator
Placebo
|
Drug: Placebo Formula 515
26 weeks, one tablet per day
|
The aim of the study is to compare the protective effect of H. pylori eradication versus PPI versus placebo on the gastric damage induced by low dose of aspirin. Treatment are attributed by randomisation. Patients are followed for 6 months and gastric damage are evaluated by endoscopy at the end of this period.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Dominique Lamarque, MD, PhD | +33(0)1 42 34 82 99 | dominique.lamarque@htd.aphp.fr |
Contact: Raphael SERREAU, MD, PhD | raphael.serreau@cch.aphp.fr |
France | |
Hotel Dieu Hospital | |
Paris, France, 75181 |
Principal Investigator: | Dominique Lamarque, MD, PhD | AP-HP |
Responsible Party: | Department Clinical Research of Developpement ( Cécile Kedzia ) |
Study ID Numbers: | P051021, AOM 05114 |
Study First Received: | June 18, 2008 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00713947 |
Health Authority: | France: Ministry of Health |
Gastric lesions induced by low dose of aspirin Helicobacter pylori |
Metronidazole Amoxicillin Heart Diseases Pantoprazole Myocardial Ischemia Vascular Diseases Coronary Thrombosis Ischemia |
Thrombosis Coronary Disease Clarithromycin Embolism and Thrombosis Aspirin Embolism Coronary Artery Disease |
Therapeutic Uses Anti-Ulcer Agents Gastrointestinal Agents Cardiovascular Diseases Pharmacologic Actions |